Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 667

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 667
---
 the BCA. If this were to occur, a restructuring of intercompany debt will be carried out between Heritas Argentina and Heritas Ltd. The restructuring involves the forgiveness of certain intercompany loans (in whose the lender is Heritas Ltd., see Note 20), which will be accounted for as capital contributions without issuing additional equity. Besides, the agreement outlines pre -mergerconditions, including SPAC shareholder redemption rights and the restructuring of OmnigenicsAI’s corporate structure to align with transaction objectives. Post -merger, OmnigenicsAI’s governance structure will include a newly constituted board of directors with representation from the participating entities, and SPAC will continue its operations under OmnigenicsAI’s oversight. However, after the reporting period, on August 27, 2024, Heritas Ltd. and MultiplAI Health Ltd. mutually agreed to terminate the Amended and Restated Share Purchase Agreement (SPA) originally executed on March 13, 2024, effectively ending MultiplAI Health Ltd.’s participation in the BCA. Despite this development, the transaction remains and is supported by other key agreements, including a Voting and Support Agreement and a Backstop Agreement to ensure the business combination fees are covered, along with compliance with U.S. securities regulations and Nasdaq listing standards. This combination establishes OmnigenicsAI as a combined entity leveraging integrated genomic and AI -drivenhealth solutions. The Group conducts its business operations through two business segments, Heritas Diagnostics and Rewell. The Heritas Diagnostics segment provides a suite of clinical genetic tests for doctors, patients, and their families, for diagnosis, prognosis and monitoring, allowing them to make informed decisions over various conditions. These tests are distributed through exclusive partnerships with clinical laboratories, empowering them to offer these advanced diagnostic services to their customers. Heritas Diagnostics products are used for reproductive genetics, oncology, genetic and rare diseases, and human microbiome testing purposes. The Rewell segment provides customers with direct access to DNA and microbiome information to enable them to make more informed long -termhealth decisions and minimize the development of chronic diseases. This includes providing F-126 Notes to Combined Financial Statements (Amounts in US Dollars, except otherwise indicated) 1.The Group’s business, reorganization and general information (cont.) health risk information through Polygenic Risk Scores (“PRS”). Customers view their results on Rewell’s proprietary digital platform, where consumers can also schedule a telemedicine consultation with a healthcare professional to interpret their results and receive a health plan with recommendations. Basis